Panel Discussion: Has the Industry Finally Solved Nose-to-Brain Delivery?

5:00 pm - Wednesday 3rd February 2027

  • Identify the critical scientific, translational, and clinical evidence gaps that remain before nose-to brain delivery can achieve widespread regulatory acceptance and commercial adoption
  • Understand what regulators still need to see regarding reproducibility, biodistribution, imaging, clinical outcomes, and direct CNS exposure before confidently supporting nose-to-brain claims
  • Debate whether current preclinical models, analytical tools, imaging technologies, and translational approaches are sufficient to predict human outcomes and support development decisions
  • Separate genuine scientific progress from industry hype by examining which technologies, pathways, and approaches are producing meaningful evidence versus those that continue to face significant validation challenges

Speakers:

Chief Scientific Officer
Neurelis
Chief Medical Officer
Vistagen
Chief Medical Officer
Oragenics
Chief Scientific Officer
Noveome Biotherapeutics